Department of Medicine and Surgery, University of Milano Bicocca , Milano , Italy.
Division of Psychiatry, University College London , London , UK.
Subst Abus. 2019;40(2):178-184. doi: 10.1080/08897077.2018.1550464. Epub 2019 Mar 18.
A dose-response association, suggesting that heavy cannabis users are more likely to report depressive disorders, has been hypothesized. However, evidence is not conclusive, and we aimed at testing the existence of a linear association between different levels of cannabis use and depressive disorders using large, representative, repeated surveys. We examined prevalence rates of different levels of past-year cannabis use and major depressive episode (MDE), separately for young people (12-17 years) and adults (18-64 years), using data between 2006 and 2015 from the National Survey on Drug Use and Health. Prevalence rates estimates with 95% confidence intervals were computed, and the association between past-year MDE and cannabis use was assessed. We then investigated whether time-period trends existed for MDE and, if so, whether these differed by cannabis use levels. Models included both time period, to evaluate trend changes in past-year MDE from 2006 to 2015, and time period by cannabis level interaction terms. Cannabis users were more likely, using both single-year and pooled survey data, to have suffered from MDE in the past year. Multiple logistic regression models, after adjusting for time period, age, and gender, showed an association between MDE and cannabis use, regardless of its levels. However, a roughly dose-response relationship was detectable only for adults. Trends in past-year MDE prevalence rates among subjects with different levels of cannabis use did not differ from trends among nonusers. Women were more likely to report concurrent past-year MDE and cannabis use than men. Cannabis users have consistently higher prevalence rates of depressive disorders compared with nonusers, suggesting the need for integrated screening and treatment programs to tackle this comorbid condition.
有一种剂量反应关联假设,即重度大麻使用者更有可能报告抑郁障碍。然而,证据并不确凿,我们旨在使用大型、代表性、重复调查来测试不同水平的大麻使用与抑郁障碍之间是否存在线性关联。我们分别检查了年轻人(12-17 岁)和成年人(18-64 岁)过去一年不同水平的大麻使用和重度抑郁发作(MDE)的流行率,使用了 2006 年至 2015 年期间全国毒品使用和健康调查的数据。计算了具有 95%置信区间的流行率估计值,并评估了过去一年 MDE 与大麻使用之间的关联。然后,我们调查了 MDE 是否存在时间趋势,如果存在,这些趋势是否因大麻使用水平而异。模型包括时间区间,以评估过去一年 MDE 从 2006 年到 2015 年的趋势变化,以及时间区间与大麻水平的交互项。大麻使用者更有可能,无论是使用单一年份还是汇总调查数据,都曾在过去一年中患有 MDE。经过时间区间、年龄和性别调整的多项逻辑回归模型表明,MDE 与大麻使用之间存在关联,无论其水平如何。然而,只有成年人才能检测到大致的剂量反应关系。在不同大麻使用水平的受试者中,过去一年 MDE 流行率的趋势与非使用者的趋势没有差异。女性报告同时患有过去一年 MDE 和大麻使用的可能性高于男性。与非使用者相比,大麻使用者的抑郁障碍患病率始终较高,这表明需要制定综合的筛查和治疗计划来解决这种共病状况。